

kování CD20+ depleční terapie. Je otázkou, zda lze komplexní interakci mezi zánětlivými a neurodegenerativními procesy adekvát-

ně řešit monoterapií záměřenou na zánět. V budoucnu by se mělo uvažovat o kombinované terapii zahrnující imunoterapii, ale

také strategie remyelinizace nebo neuroprotektivní léčby, která nám v současné době chybí (Havla et Hohlfeld, 2022).

## LITERATURA

1. Anolik JH, Campbell D, Felgar RE, et al. The relationship of Fc-gammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. *Arthritis and rheumatism*. 2003;48(2):455-459.
2. Barkhof F, Kappos L, Wolinsky JS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. *Neurology*. 2019;93(19):e1778-e1786.
3. Bar-Or A, O'Brien SM, Sweeney ML, et al. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. *CNS drugs*. 2021;35(9):985-997.
4. Bhargava P, Wicken C, Smith MD, et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. *Multiple sclerosis and related disorders*. 2019;30:136-140.
5. Correale J, Gaitán MI, Ysraelit MC, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. *Brain: a journal of neurology*. 2017;140(3):527-546.
6. Disanto G, Barro C, Benkert P, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. *Annals of neurology*. 2017;81(6):857-870.
7. Fereidan-Esfahani M, Brück W, Weber MS. Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option? *JAMA neurology*. 2015;72(12):1407-1408.
8. Filippi M, Preziosa P, Langdon D, et al. Identifying Progression in Multiple Sclerosis: New Perspectives. *Annals of neurology*. 2020;88(3):438-452.
9. Giovannoni G, Kappos L, de Seze J, et al. Long-Term Reduction of Relapse Rate and Confirmed Disability Progression after 7.5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis in the OPERA OLE. ECTRIMS 2021.
10. Hauser SL, Kappos L, Montalban, et al. Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis. ECTRIMS 2021.
11. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *The New England journal of medicine*. 2017;376(3):221-234.
12. Hauser SL, Bar-Or A, Weber MS, et al. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. *Neurology(R) neuroimmunology & neuroinflammation*. 2023;10(2):e20094. DOI: 10.1212/NXI.0000000000200094.
13. Havla J, Hohlfeld R. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. *Neurotherapeutics: the journal of the American Society for Experimental Neuro Therapeutics*. 2022;19(3):774-784.
14. Healy BC, Glanz BI, Swallow E, et al. Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. *Multiple sclerosis journal – experimental, translational and clinical*. 2021;7(2): 2055217321999070.
15. Hohlfeld R, Dornmair K, Meinl E, et al. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. *Lancet neurology*. 2016;15(3):317-331.
16. Kappos L, Hartung HP, Hauser SL, et al. Eight-Year Analyses of Repeated Confirmed Disability Progressions in the OPERA I/II and ORATORIO Studies and Their Open-Label Extensions. ECTRIMS 2022.
17. Kappos L, Wolinsky JS, Giovannoni G, et al. Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). *Journal of Neurology, Neurosurgery, and Psychiatry*. 2018;89(6):A25.2-A25.
18. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. *Lancet neurology*. 2023; 22(1):78-88.
19. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014; 83(3): 278-286.
20. Martin M del P, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. *Archives of neurology*. 2009;66(8):1016-1020.
21. Meinl E, Hohlfeld R. CD20 T Cells as Pathogenic Players and Therapeutic Targets in MS. *Annals of neurology*. 2021;90(5): 722-724.
22. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. *The New England journal of medicine*. 2017;376(3):209-220.
23. Montalban X, Matthews PM, Simpson A, et al. Real-world evaluation of ocrelizumab in multiple sclerosis: a systematic review. *Annals of clinical and translational neurology*. 2023;10(3):302-311.
24. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. *Nature medicine*. 2008;14(6):688-693.
25. Portaccio E, Bellinva A, Fonderico M, et al. Progression independent of relapse activity in early multiple sclerosis: a real-life cohort study. *Brain: a journal of neurology*. 2022;145(8):2796-2805.
26. Preziosa P, Rocca MA, Filippi M. Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring. *Expert review of neurotherapeutics*. 2022;20(8):747-769.
27. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. *Blood*. 2003;101(2):466-468.
28. Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. *Journal of neurology*. 2019;266(5):1182-1193.
29. Wolinsky JS, Montalban X, Hauser SL, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. *Annals of neurology*. 2018;84(4):527-536.
30. Wolinsky JS, Vermersch P, Hartung HP, et al. Sustained Reduction in 48-Week Confirmed Disability Progression in Patients with PPMS Treated with Ocrelizumab in the ORATORIO OLE: 8-Year Follow-Up. ECTRIMS 2022.

# Připravujeme do příští Neurologie pro praxi

2023

4

- **Hlavní téma** – Paroxysmální neepileptické stavy v neurologii
- **Přehledové články** – Nejčastější chyby v diagnostice roztroušené sklerózy, Vaskulární epilepsie, Fyzikální příčiny profesionálních neuropatií, Kognitivní deficit u chronických migreniků
- **Z pomezí neurologie** – Současná doporučení pro využití MR u onemocnění roztroušené sklerózy v klinické praxi
- **Sdělení z praxe** – Progresivní multifokální leukoencefalopatie jako prvotní oportunní infekce u pacienta s AIDS, Tuberkulom, nebo tuberkulózní absces?, Funkční tiková porucha: hromadná nákaza ze sociálních sítí?

... a spoustu dalších zajímavých témat

▼  
VYJDE  
V ZÁŘÍ

**SOLEN**  
MEDICAL EDUCATION